Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use.
Warren Apel1, Ye Li1
1Department of Ophthalmology, Sunshine Coast University Hospital, QLD, Australia.
Journal of Vitreoretinal Diseases
|April 28, 2025
Summary
Bullous central serous chorioretinopathy (CSCR) developed in a patient taking a Janus kinase (JAK) inhibitor. Focal laser treatment successfully resolved the condition, restoring visual acuity.
Area of Science:
- Ophthalmology
- Rheumatology
Background:
- Central serous chorioretinopathy (CSCR) is a condition affecting vision.
- Bullous CSCR is a rare subtype characterized by subretinal fluid and pigment epithelial detachment.
Observation:
- A patient with rheumatoid arthritis developed bullous CSCR after initiating upadacitinib, a JAK inhibitor.
- Ophthalmic examination revealed retinal detachment and subretinal fluid in the macula.
- Optical coherence tomography confirmed subretinal fibrin and pigment epithelial detachment.
Findings:
- Focal laser treatment was administered for the bullous CSCR.
- One year post-treatment, the patient's visual acuity improved to 20/20.
- Subretinal fluid resolved completely following the laser intervention.
Implications:
- Upadacitinib may be linked to bullous CSCR development, potentially via coagulation cascade disruption.
- Focal laser therapy is an effective treatment for this uncommon presentation of CSCR.
- This case highlights the importance of monitoring for ophthalmic side effects of JAK inhibitors.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K
01:27Open Angle Glaucoma: Treatment
356
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
356
01:28Angle Closure Glaucoma: Treatment
365
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
365
01:25Glaucoma: Overview
469
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
469
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
100
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
100